Literature DB >> 26238709

[Treat to participation : Position paper of the German Society for Rheumatology on sustained improvement of functional health of patients with rheumatic and musculoskeletal diseases].

W Mau1, W Beyer, I Ehlebracht-König, J-M Engel, E Genth, U Lange.   

Abstract

From the perspective of patients with rheumatic diseases, the reduction of inflammatory disease activity alone is not a sufficient treatment goal. In addition the functional health and participation also have to be improved. Starting with the first symptoms the empowerment for the self-management of the disease is important for the patients; therefore, the established treat to target-strategy has to be expanded by the functional dimension to treat to participation. The position paper of the German Society for Rheumatology (GSR) summarizes the relevant fields of the multiprofessional action that is frequently necessary. This includes the acquirement of function-related competencies during training, further education and advanced training as well as implementation in the everyday practice of patient care. Furthermore, the GSR acknowledges the need for research related to functional and sociomedical consequences of rheumatic diseases and to individual and combined function-related programs in outpatient and inpatient care in rheumatology.

Entities:  

Mesh:

Year:  2015        PMID: 26238709     DOI: 10.1007/s00393-015-1640-z

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  24 in total

1.  [Inpatient rheumatology treatment in Germany].

Authors:  J Kekow
Journal:  Z Rheumatol       Date:  2014-03       Impact factor: 1.372

2.  [Trends in rehabilitation of patients with rheumatic diseases in Germany].

Authors:  W Mau; W Beyer; I Ehlebracht-König; J-M Engel; E Genth; W H Jäckel; U Lange; K Thiele
Journal:  Z Rheumatol       Date:  2014-03       Impact factor: 1.372

3.  [Memorandum on the position and development of rehabilitation for patients with rheumatic diseases].

Authors:  W H Jäckel; W F Beyer; U Droste; M Engel; E Genth; H G Pott; K L Schmidt
Journal:  Z Rheumatol       Date:  1996 Nov-Dec       Impact factor: 1.372

4.  [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 9 International classification of functioning, disability and health (ICF)].

Authors:  U Kiltz; W Mau; U Repschläger; E Böhle; J Braun
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

5.  [The patient as the center of attention: patient-reported outcome].

Authors:  R Alten; M Schneider
Journal:  Z Rheumatol       Date:  2014-10       Impact factor: 1.372

6.  Mortality risk by functional status and health-related quality of life in patients with rheumatoid arthritis.

Authors:  Kaleb Michaud; Montserrat Vera-Llonch; Gerry Oster
Journal:  J Rheumatol       Date:  2011-11-15       Impact factor: 4.666

Review 7.  [Treat-to-target from the patient perspective].

Authors:  E Gromnica-Ihle; M Rink
Journal:  Z Rheumatol       Date:  2011-10       Impact factor: 1.372

8.  [Outpatient rheumatologic treatment in Germany].

Authors:  E Edelmann
Journal:  Z Rheumatol       Date:  2014-03       Impact factor: 1.372

Review 9.  [Patient-centredness in rehabilitation : an overview on the current state of research].

Authors:  E Farin
Journal:  Z Rheumatol       Date:  2014-02       Impact factor: 1.372

10.  Evolution of cost structures in rheumatoid arthritis over the past decade.

Authors:  Dörte Huscher; Thomas Mittendorf; Ulrich von Hinüber; Ina Kötter; Guido Hoese; Andrea Pfäfflin; Sascha Bischoff; Angela Zink
Journal:  Ann Rheum Dis       Date:  2014-01-09       Impact factor: 19.103

View more
  5 in total

1.  [Standards of care for people with rheumatoid arthritis in Europe : Translation and comments of the eumusc.net recommendations supported by EULAR performed by a national task force of the professional organisations DGRh and VRA supported by "Deutsche Rheumaliga"].

Authors:  J Braun; A Krause; M Aringer; G Burmester; F Bessler; J-M Engel; U Faubel; R Fischer-Betz; E Genth; E Gromnica-Ihle; B Hellmich; I Kötter; K Krüger; J Lakomek; H-M Lorenz; B Manger; E Märker-Hermann; K Minden; U Müller-Ladner; J Rautenstrauch; S Rehart; G Riemekasten; M Rudwaleit; W Rüther; G Schett; F Schuch; H Schulze-Koops; C Specker; S Wassenberg; D Wiek; A Zink; M Schneider
Journal:  Z Rheumatol       Date:  2016-05       Impact factor: 1.372

2.  [Memorandum of the German Society for Rheumatology on the quality of treatment in rheumatology - Update 2016].

Authors:  A Zink; J Braun; E Gromnica-Ihle; D Krause; H J Lakomek; W Mau; U Müller-Ladner; J Rautenstrauch; C Specker; M Schneider
Journal:  Z Rheumatol       Date:  2017-04       Impact factor: 1.372

3.  [Cornerstones of quality assurance in medicine in Germany. Important impulse for the situation in treatment of rheumatism].

Authors:  J Braun; M Schneider; H-J Lakomek
Journal:  Z Rheumatol       Date:  2016-03       Impact factor: 1.372

Review 4.  [Complex treatments in rheumatology and geriatrics - Challenges - Differences - Chances].

Authors:  H-J Lakomek; W Fiori
Journal:  Z Rheumatol       Date:  2018-06       Impact factor: 1.372

5.  [Quality in acute inpatient rheumatology 2021 : Current aspects of the KOBRA quality label of the Association of Rheumatological Acute Care Clinics].

Authors:  H-J Lakomek; M Rudwaleit; A Hentschel; B Broge; J Abrolat; F Bessler; B Hellmich; A Klemann; A Krause; M Klass; J Strunk; W Fiori; N Roeder; J Braun
Journal:  Z Rheumatol       Date:  2021-05-17       Impact factor: 1.372

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.